ELOQUENT-2 Study in Patients With Relapsed/Refractory Multiple Myeloma
Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses the ELOQUENT-2 study in patients with relapsed/refractory multiple myeloma.
The trial was based on results from early phase I/II trials that showed that elotuzumab and lenalidomide are synergistic when given together, said Lonial. There was also a better overall response rate and longer progression-free survival with the addition of elotuzumab.
Lonial says more than 300 patients were randomized to each arm, and roughly one-third of patients had high-risk disease at the time of initial presentation.
Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses the ELOQUENT-2 study in patients with relapsed/refractory multiple myeloma. This was a randomized phase III trial that evaluated the benefit of elotuzumab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone without elotuzumab.
Fellow's Perspective: Impact of Quadruplet and MRD in Newly Diagnosed Multiple Myeloma
December 17th 2024In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma.
Read More
